CDXS
Codexis Inc.

2,244
Mkt Cap
$153.55M
Volume
502,506.00
52W High
$5.43
52W Low
$1.52
PE Ratio
-2.24
CDXS Fundamentals
Price
$1.68
Prev Close
$1.70
Open
$1.70
50D MA
$1.78
Beta
2.14
Avg. Volume
1.17M
EPS (Annual)
-$0.8892
P/B
3.94
Rev/Employee
$315,664.89
Loading...
Loading...
News
all
press releases
Telemark Asset Management LLC Increases Stock Position in Codexis, Inc. $CDXS
Telemark Asset Management LLC lifted its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 33.3% during the second quarter, according to its most recent disclosure with the...
MarketBeat·2mo ago
News Placeholder
More News
News Placeholder
Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS)
Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks·2mo ago
News Placeholder
Codexis (NASDAQ:CDXS) Rating Lowered to "Strong Sell" at Wall Street Zen
Wall Street Zen downgraded shares of Codexis from a "hold" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
Codexis (NASDAQ:CDXS) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS
Codexis (NASDAQ:CDXS - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by...
MarketBeat·2mo ago
News Placeholder
Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -46.67% and -53.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.39% and -85.07%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +14.29% and +2.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing Codexis and Nitto Denko Avecia Enter Evaluation...
PR Newswire·2mo ago
News Placeholder
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +5.88% and +2.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
<
1
2
...
>

Latest CDXS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.